Key terms
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SRPT news
Yesterday
3:33pm ET
Young boy dies in trial of Pfizer DMD gene therapy, STAT reports
May 03
7:16am ET
Sarepta price target lowered to $175 from $177 at JPMorgan
May 02
8:27am ET
Sarepta price target raised to $173 from $167 at UBS
May 02
7:57am ET
Cantor Fitzgerald Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)
May 02
7:25am ET
Buy Rating on Sarepta Therapeutics Backed by Elevidys’s Market Expansion and FDA Approval Prospects
May 02
6:55am ET
Buy Rating on Sarepta Therapeutics Affirmed Amid Elevidys Regulatory Progress and Portfolio Strength
May 02
6:45am ET
Buy Rating on Sarepta Therapeutics Amid Anticipated Label Expansion for Elevidys
May 02
6:36am ET
RBC Capital Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
May 02
6:23am ET
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), Sarepta Therapeutics (SRPT) and Acadia Healthcare (ACHC)
May 02
3:51am ET
Analysts Are Bullish on These Healthcare Stocks: Stryker (SYK), Sarepta Therapeutics (SRPT)
May 02
3:50am ET
Barclays Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
May 01
4:48pm ET
Sarepta reports Q1 EPS 73c, consensus (7c)
May 01
7:56am ET
Oppenheimer Sticks to Their Hold Rating for Sarepta Therapeutics (SRPT)
Apr 30
6:53am ET
Biotech Sector: M&A Fuels Renewed Excitement
Apr 26
2:07am ET
Optimistic Outperform Rating on Sarepta Therapeutics Amid Strong Elevidys Demand and Potential Label Expansion
Apr 19
7:12am ET
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Sarepta Therapeutics (SRPT) and Intuitive Surgical (ISRG)
Apr 08
10:00pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ)
Apr 04
7:46pm ET
Buy Rating on Sarepta Therapeutics Amidst Anticipated Drug Approval and Market Potential
Mar 22
7:56am ET
Oppenheimer Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)
Mar 13
5:45am ET
Sarepta Therapeutics: A Strong Buy on Promising Drug Outlook and Strategic Growth Potential
Mar 13
2:35am ET
Buy Rating for Sarepta Therapeutics Amidst Promising Developments and Strategic Partnerships
Mar 07
8:17am ET
PepGen price target lowered to $20 from $21 at Wedbush
Mar 06
7:26am ET
Sarepta Therapeutics’ Elevidys Poised for Market Leadership in DMD, Despite Emerging Competitors
Mar 06
6:31am ET
Analysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), 2seventy bio (TSVT)
Mar 01
7:48am ET
Sarepta Therapeutics (SRPT) Gets a Hold from Oppenheimer
Mar 01
7:19am ET
Sarepta price target raised to $167 from $164 at UBS
Mar 01
1:31am ET
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Alcon (ALC) and Sarepta Therapeutics (SRPT)
Mar 01
1:12am ET
Sarepta Therapeutics: A Strong Buy on Robust Financials and Promising Clinical Advancements
Mar 01
12:55am ET
Buy Rating Affirmed for Sarepta Therapeutics as Elevidys Shows Strong Sales and Promising Outlook
Feb 29
8:29am ET
Sarepta price target raised to $157 from $151 at RBC Capital
Feb 29
7:31am ET
Analysts Are Bullish on These Healthcare Stocks: Addus Homecare (ADUS), Jazz Pharmaceuticals (JAZZ)
No recent press releases are available for SRPT
SRPT Financials
Key terms
Ad Feedback
SRPT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SRPT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
